Patent · US Active

Controlled-release CNP agonists with reduced side-effects

US11389511B2 · kind B2 · utility

4Cited by

11References

16Claims

0Family size

Assignee

ASCENDIS PHARMA GROWTH DISORDERS A/S · DK

Inventors

Kennett Sprogøe · Rudegård, DK
Harald Rau · Würzburg, DE
Felix Cleemann · Mainz, DE
Ulrich Hersel · Heidelberg, DE
Caroline Elisabeth Rasmussen · Frederiksdal, DK

Key dates

Filing date	Jan 5, 2017
Grant date	Jul 19, 2022
Priority date	—
Expiry date	Jan 5, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P19/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.